Category and Product-level Procurement and Delivery Planning Guide
|
|
|
- Kelly Benson
- 5 years ago
- Views:
Transcription
1 Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global Fund s Pooled Procurement Mechanism. This information may also be useful as a reference for other procurement channels. Procurement and delivery lead-time information is the time from making a procurement request to delivery in country and assumes that there are no financing or other challenges that may delay confirming an order. This information is provided at the category and the detailed product level and is indicative based on current market knowledge to assure on-time delivery and best value procurement in terms of product and freight costs. Health Technologies Viral Load, hematology, chemistry, CD4 equipment and reagents are dependent on procurement volumes, country importation requirements and manufacturer production schedules. Actual lead times will be confirmed at time of order placement. For planning purposes, please factor in minimum 6 months timeline. The lead-time information is updated from time to time. The most recent version of this guidance is available here. 1
2 October September August July June May April March February January December November October September August July June Latest indicative date order date for reliable supply and best value Category level indicative procurement planning timeline guide Note that there may be some variations within the category -please consult the attached detailed product level list for more specific guidance Optimal high volume ARVs Specialist-or limited use ARVs HIV Malaria To find the required order month, select the date products required in country 2018 Apr-19 May-19 Other medicines HIV Rapid tests Condoms & lubricants HIV Viral Load** HIV Early Infant Diagnosis** CD4 / Chemistry / Hematology Laboratory*** Consumables AL nondispersible; ASAQ 2019 Due to short shelf life, dependent on manufacturer production schedule at time of order placement. Apr-19 May-19 AL dispersible Late/emergency order July-18 Aug-18 Sept-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 Apr-19 May-19 Artesunate injection Seasonal malaria chemoprevention (AQ+SP) Other ACTs and antimalarial medicines # Late/emergency order Jul-18 Aug-18 Sept-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Late/emergency order Jul-18 Aug-18 Sept-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Rapid tests LLINs IRS Late/emergency order Jun-18 July-18 Aug-18 Sept-18 Oct-18 Nov-18 Dec-18 # Wide variation please consult detailed product-level guidance 2
3 Category/Sub-category/Product ACTs Artemether/Lumefantrine Artemether/Lumefantrine 20/120mg 12 tablet 30 blister Artemether/Lumefantrine 20/120mg 18 tablet 30 blister Artemether/Lumefantrine 20/120mg 24 tablet 30 blister Artemether/Lumefantrine 20/120mg 6 tablet 30 blister Artemether/Lumefantrine - dispersible Artemether/Lumefantrine 20/120mg 12 tablet dispersible 30 blister Artemether/Lumefantrine 20/120mg 6 tablet dispersible 30 blister Artesunate/Amodiaquine Artesunate/Amodiaquine 100/270mg 3 tablet 25 blister Artesunate/Amodiaquine 100/270mg 6 tablet 25 blister Artesunate/Amodiaquine 25/67.5mg 3 tablet 25 blister Artesunate/Amodiaquine 50/135mg 3 tablet 25 blister Other ACTs and antimalarial medicines Artesunate+Sulfadoxine/Pyrimethamine 100mg+500/25mg 6+3 tablet co-blistered 25 blister Artesunate+Sulfadoxine/Pyrimethamine 50mg+500/25mg 6+2 tablet co-blistered 25 blister Artesunate/Mefloquine 25/50mg 3 tablet 30 blister Artesunate/Mefloquine 25/50mg 6 tablet 30 blister Artesunate/Mefloquine 100/200mg 3 tablet 30 blister Artesunate/Mefloquine 100/200mg 6 tablet 30 blister Artesunate 60mg powder for solution for injection - 1 vial Artesunarte suppositoire 100mg; 2 Amodiaquine (as hydrochloride)+sulfadoxine/pyrimethamine 153mg+500/25mg 3+1 tablet dispersible co-blistered 50 blister Amodiaquine (as hydrochloride)+sulfadoxine/pyrimethamine 76.5mg+250/12.5mg 3+1 tablet dispersible co-blistered 50 blister Sulfadoxine/Pyrimethamine 500/25mg 3 tablet 10 blister Sulfadoxine/Pyrimethamine 500/25mg 3 tablet 100 blister Sulfadoxine/Pyrimethamine 500/25mg tablet 100 bulk Sulfadoxine/Pyrimethamine 500/25mg tablet 1000 bulk Primaquine 7.5mg (as base) (equivalent to 13.2mg Primaquine Phosphate) tablet 1000 Primaquine 7.5mg (as base) (equivalent to 13.2mg Primaquine Phosphate) 10 tablet 10 blister Primaquine 7.5mg (as base) (equivalent to 13.2mg Primaquine Phosphate) 10 tablet 100 blister Chloroquine (as Phosphate) 250mg as phosphate (155mg as base) 100 tablet Chloroquine (as Phosphate) 250mg as phosphate (155mg as base) 1000 tablet 3
4 Chloroquine (as Phosphate) 250mg as phosphate (155mg as base) 10 tablet 10 blister Chloroquine (as Phosphate) 250mg as phosphate (155mg as base) 100 tablet 10 blister Malaria Rapid Diagnostic Test LLINs Malaria Rapid Diagnostic Test Kit -Antigen Pf/Pan - POCT - 25 x 1 test Malaria Rapid Diagnostic Test Kit - Antigen Pf - 25 tests Malaria Rapid Diagnostic Test Kit - Antigen Pf - POCT - 25 x 1 test Malaria Rapid Diagnostic Test Kit - Antigen Pf / Pv -POCT - accessories included - 25 x 1 test Malaria Rapid Diagnostic Test Kit - Antigen Pf / Pv - accessories included - 25 tests Malaria Rapid Diagnostic Test Kit - Antigen Pf/Pan - 25 tests LLIN Pyrethroids LLIN PBO LLIN Next Generation IRS (Indoor Residual Spray) *Not Exhaustive list refer to Global Fund QA Policy for additional products* ARVs Alpha-cypermethrin (Suspension Concentrate) 1 Litre Alpha-cypermethrin (Wettable Powder (WP) 150g Bendiocarb (Wettable Powder (WP) 20g Bendiocarb (Wettable Powder (WP) 62.5g Bendiocarb (Wettable Powder (WP) 125g Bendiocarb Wettable Powder in Water Soluble Bags (WP-SB) 100g Clothianidin 50% (Water Dispersible Granules (WG) 150g Deltamethrin (Water Dispersible Granules (WG) 20g Deltamethrin (Water Dispersible Granules (WG) 25g Deltamethrin (Wettable Powder (WP) 5.5kg Dichlorodiphenyltrichloroethane (DDT) (Wettable Powder (WP) 670g Lambda-cyhalothrin (Capsule Suspension (CS) 62.5ml Pirimiphos-methyl (Capsule Suspension (CS) 833ml WHO Recommended Optimal Abacavir/Lamivudine 120/60mg tablet dispersible 30 Abacavir/Lamivudine 120/60mg tablet dispersible 60 Abacavir/Lamivudine 60/30mg tablet dispersible 60 Abacavir/Lamivudine 600/300mg tablet 30 Atazanavir/Ritonavir 300/100mg tablet 30 Dolutegravir 50mg tablet 30 Dolutegravir/Lamivudine/Tenofovir 50/300/300mg tablet 30 Efavirenz 200mg tablet double scored 90 Efavirenz 200mg tablet single scored 90 Efavirenz 600mg tablet 30 Efavirenz/Emtricitabine/Tenofovir 600/200mg/300mg tablet 30 Efavirenz/Lamivudine/Tenofovir 600/300/300mg tablet 30 Efavirenz/ Lamivudine /Tenofovir 400/300mg/300mg tablet 30 Emtricitabine/Tenofovir 200/300mg tablet 30 Lamivudine/Nevirapine/Zidovudine 150/200mg/300mg tablet 60 Lamivudine/Nevirapine/Zidovudine 30/50/60mg tablet dispersible 60 4
5 Lamivudine/Tenofovir 300/300mg tablet 30 Lamivudine/Zidovudine 150/300mg tablet 60 Lamivudine/Zidovudine 30/60mg tablet dispersible 60 Lopinavir/Ritonavir 100/25mg tablet 60 Lopinavir/Ritonavir 200/50mg tablet 120 Lopinavir/Ritonavir 80/20mg/ml oral solution 60ml*5 Lopinavir/Ritonavir 40/10mg capsule/pellets 120 Nevirapine 10mg/ml oral suspension 100ml Nevirapine 200mg tablet 60 Nevirapine 50mg tablet dispersible 60 Specialist or Limited-Use Abacavir 20mg/ml oral solution 240ml Abacavir 300mg tablet 60 Abacavir 60mg tablet dispersible 60 Abacavir/Lamivudine/Zidovudine 300/150/300mg tablet 60 Atazanavir 150mg capsule 60 Atazanavir 200mg capsule 60 Atazanavir 300mg capsule 30 Darunavir 400mg tablet 60 Darunavir 600mg tablet 60 Efavirenz 200mg tablet 30 Efavirenz 50mg tablet 30 Lamivudine 10mg/ml oral solution 100ml Lamivudine 150mg tablet 60 Lamivudine/Zidovudine+Efavirenz 150/ mg tablet coblistered 90 Nevirapine 100mg tablet dispersible 60 Ritonavir 100mg tablet 60 Ritonavir 80mg/ml oral solution 90ml Tenofovir 300mg tablet 30 Zidovudine 300mg tablet 60 Zidovudine 50mg/5ml Oral solution 100ml Zidovudine 50mg/5ml Oral solution 240ml HIV Rapid Diagnostic Test HIV 1/2 Bioline 3.0 Kit -accessories included - 25 tests HIV 1/2 Bioline 3.0 Kit - no accessories - 30 tests HIV 1/2 - Determine HIV Combo Kit - no accessories tests HIV 1/2 - Bioline HIV/Syphilis Duo complete kit - accessories included - 25 tests HIV 1/2-O - First Response HIV v.3.0 Cards Kit - accessories included - 25 tests HIV 1/2-O - First Response HIV v.3.0 Cards Kit - accessories included - 30 tests HIV Bioline Ag/Ab Combo Kit - no accessories - 30 tests HIV Chase Buffer - for Determine - 2.5ml vial tests HIV Determine Complete HIV Kit incl. accessories tests HIV Determine HIV Kit- no accessories tests 5
6 HIV INSTI HIV Antibody Test Kit - 48 tests HIV OraQuick HIV Rapid Antibody Kit - accessories included -100 Tests HIV Stat-Pak Dipstick Assay Kit - accessories included - 30 tests HIV Stat-Pak HIV Kit - accessories included - 20 tests HIV Uni-gold HIV Kit - accessories included -20 tests HIV Vikia HIV Device Kit - accessories included -25 tests HIV Oraquick Self-Test 50 tests HIV Oraquick Self-Test 250 tests HIV Atomo Self-Test -1 test HIV INSTI Self-Test -1 test HIV BioSure Self-Test -1 test HIV Sure Check HIV Self-Test -1 test Condoms Female condom Male condom -pack of 144 Lubricants Lubricant -35 g - sterile jelly - 1 tube Lubricant - 82 g - sterile jelly - 1 tube Lubricant 4-5 ml - water based sachets Viral Load Abbott Viral Load / EID + consumables Qiagen Hologic Cepheid BioMerieux Biocentric Viral Load + consumables Viral Load + consumables Viral Load / EID Viral Load Viral Load + consumables Roche Viral Load / EID + consumables 6
Invitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
Supplier/ Manufacturer(s) Unit III, Survey No 51, Plot No IDA, Jeedimetla, Hyderabad, Telangana, Hetero labs limited
LIST OF DELISTED PRODUCTS Not eligible for procurement with the Global Fund resources 06th of April 2018 Delisted Mar-18 Ritonavir (RTV) 0 mg Tablet Unit Survey No 51, Plot No 22-1 IDA, Jeedimetla, Hyderabad,
Summary of the Report as of 1st February 2017
MINISTRY OF HEALTH PHARMACY DIVISION Stock Status Report 1st February 2017 A Publication of The Ministry of Health Uganda The purpose of this report is to inform the Ministry of Health and all stakeholders
MINISTRY OF HEALTH PHARMACY DIVISION STOCK STATUS REPORT AS AT 2017 A
MINISTRY OF HEALTH PHARMACY DIVISION STOCK STATUS REPORT AS AT 1st August 2017 A Publication of The Ministry of Health Uganda The purpose of this report is to inform the Ministry of Health and all stakeholders
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
AccuSet HIV-1/2 Performance Panel
OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple
There are a number of vector control procedures that should be considered to
Appendix F: Vector Control Procedures There are a number of vector control procedures that should be considered to mitigate the risk of CHIKV expansion in an area (Table F1). Table F1. Vector Control Procedures
CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013
istry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013 Introduction The purpose of this report is to inform the istry of Health and all stakeholders of the stock levels in the country
UNICEF AND MALARIA MEDICINES. Supply Division October 2006
UNICEF AND MALARIA MEDICINES Supply Division October 2006 PROCUREMENT SERVICES SUPPORTING CHILD RIGHTS UNICEF PROVIDES PROCUREMENT SERVICES AS PART OF ITS MANDATE Helping partners access resources for
Interpretation of the World Malaria Report Country Profile
Interpretation of the World Malaria Report Country Profile Acknowledgements This presentation was developed to help explain the components of the World Malaria Report Country Profile. The 2017 World Malaria
100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010
Currently Approved CBER Device Premarket Applications (PMAs) As of Nov 10, 2014 Sorted by Applicant Name BP090080-0 BP060002-0 BP120037-0 BP090022-0 BP090032-0 BP040046-0 BP100064-0 BP140120-0 Abbott Laboratories
Priority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
HIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center
HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated
WHO list of prequalified in vitro diagnostic products
WHO list of in vitro diagnostic products : Rest of the world. Regulatory version applied to products not approved by stringent/mature NRAs or not regulated Last update: 21 December 2016 Year 2016 HIV RDT
WHO list of prequalified in vitro diagnostic products
WHO list of prequalified in vitro diagnostic products : Rest of the world. Regulatory version applied to products not approved by stringent/mature NRAs or not regulated Last update: 17 March 2017 Year
WHO list of prequalified in vitro diagnostic products
WHO list of prequalified in vitro diagnostic products : Rest of the world. Regulatory version applied to products not approved by stringent/mature NRAs or not regulated Last update: 22 December Year prequalified
Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
WHO list of prequalified in vitro diagnostic products
WHO list of in vitro diagnostic products : Rest of the world. Regulatory version applied to products not approved by stringent/mature NRAs or not regulated Last update: 8 April 2016 Year 2016 HIV RDT OraQuick
Paediatric ART Working Group. guideline review meetings
Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
UNITAID. AMDS Partners Meeting. UNITAID Strategy & 2013 Call for Letters of Intent. Brenda Waning. Page 1
Page 1 UNITAID AMDS Partners Meeting UNITAID 2013-2016 Strategy & 2013 Call for Letters of Intent Brenda Waning Geneva 7 May, 2013 UNITAID s Six Strategic Objectives SO1: Increase access to simple, point-of-care
WHO list of prequalified in vitro diagnostic products
: Rest of the world. Regulatory version applied to products not approved by stringent/mature NRAs or not regulated 2018 CD4 Muse Auto CD4/CD4% kit MCA100101, MCA500101, MCA1XK101 EMD Millipore Corporation
GPRM - Global Price Reporting Mechanism November Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009 A summary report from the Global Price Reporting Mechanism Contents Abbreviations. 5 Table 1 : of first-line
A Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
Global Fund Approach to Health System Strengthening
Global Fund Approach to Health System Strengthening WHO Expert consultation on positive synergies between health systems and Global Health Initiatives Geneva, 29-30 May 2008 Dr Stefano Lazzari, Director
Nutrition Procurement Overview
Nutrition Procurement Overview RUTF Pre-tender Industry Consulation Copenhagen, 11-13 June 2018 Click to edit Master subtitle style Supply Division Structure (2018-2021) Director Deputy Director Programme
SHOKI AL DOBAI, Ph.D. Pesticide Directorate, GDPP Ministry of Agriculture & Irrigation, Yemen
SHOKI AL DOBAI, Ph.D. Pesticide Directorate, GDPP Ministry of Agriculture & Irrigation, Yemen Problems of vector borne diseases Malaria; Leishmaniasis; Rift Valley Fever; Dengue Fever; Other vectors/ Pest
BREATH AND BLOOD ALCOHOL STATISTICS
BREATH AND BLOOD ALCOHOL STATISTICS 116 MOTOR VEHICLE CRASHES IN NEW ZEALAND 213 BREATH AND BLOOD ALCOHOL STATISTICS 117 CONTENTS TABLES Table 1 Number of alcohol offenders by age group and sex 119 Table
Paediatric HIV Resistance Referal Pathway. Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal
Paediatric HIV Resistance Referal Pathway Mohern Archary Paediatric Infectious Diseases Unit King Edward VIII Hospital / University of KwaZulu Natal Third line Antiretroviral treatment options in HIV positive
Global Fund & CCCMHPIE Supplier Conference
Global Fund & CCCMHPIE Supplier Conference - Mariatou Tala Jallow - Lin (Roger) Li - Martin Auton - Ming Xu 22 November 2017 Beijing, China Key contacts: The Global Fund Sourcing Department Patrick Latin
The Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
Overview of Malaria Epidemiology in Ethiopia
Overview of Malaria Epidemiology in Ethiopia Wakgari Deressa, PhD School of Public Health Addis Ababa University Symposium on Neuro-infectious Disease United Nations Conference Center, AA February 28,
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
Routine HIV Testing Community of Practice Session #2
Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing
Medicines recommended to prevent and manage the priority diseases at the community and health facility level
s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths
The Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
AWMSG Secretariat Assessment Report Advice no Darunavir (Prezista
AWMSG Secretariat Assessment Report Advice no. 0311 Darunavir (Prezista ) for the treatment of HIV-1 infection in treatment-experienced children and adolescents This assessment report is based on evidence
Malaria Incidence and Malaria Control Interventions among Under 5 s: Epidemic districts of Northern Uganda, July 2012-June 2015
Public Health Fellowship Program Field Epidemiology Track among Under 5 s: Epidemic districts of Northern Uganda, July 2012-June 2015 Allen Eva Okullo, MPH, BSc. Zoo/Psy PHFP-FET Cohort 2015 Malaria Burden
AMENDMENTS TO THE SECOND REVISION OF THE FIRST EDITION OF THE MANUAL ON DEVELOPMENT AND USE OF FAO AND WHO SPECIFICATIONS FOR PESTICIDES
AMENDMENTS TO THE SECOND REVISION OF THE FIRST EDITION OF THE MANUAL ON DEVELOPMENT AND USE OF FAO AND WHO SPECIFICATIONS FOR PESTICIDES Page Current text Revised text Notes P.21 A. 10.1. WHO classification
The Three Millennium Development Goal Fund A guide for the selection of Malaria Rapid Diagnostic Test kits purchased with 3MDG grants
The Three Millennium Development Goal Fund A guide for the selection of Malaria Rapid Diagnostic Test kits purchased with 3MDG grants Version 4.0 February 2014 1. Contents A GUIDE FOR THE SELECTION OF
List of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
HIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
Il programma dei farmaci essenziali dell OMS, la nuova lista marzo Suzanne Hill Department of Medicines Policy and Standards WHO
Il programma dei farmaci essenziali dell OMS, la nuova lista marzo 2007 Suzanne Hill Department of Medicines Policy and Standards WHO Essential medicines 30 years on Outline A review of 30 years of essential
An Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children
Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/r) Formulation on WHO Model List of Essential Medicines for Children Table of Contents 1. Summary statement of proposal for inclusion...
Improving care of HIV-infected breastfeeding
Improving care of HIV-infected breastfeeding and their : Early results from the Partnership for HIV-free Survival Initiative in Uganda Tamara Nsubuga-Nyombi, URC IAS- Melbourne, Australia July 22nd, 2014
HIV-1 AccuVert TM Seroconversion Panel
PACKAGE INSERT PRB954 (0600-0238) INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot test methods. Characterized
Malaria and HIV infection
Malaria and HIV infection Philip Rosenthal Dept. of Medicine UCSF The co-epidemics of malaria and HIV infection Malaria 300-500 million episodes each year (~90% in Africa) Over 1 million deaths each year
What's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
Drug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand
Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012 GPO s Profile GPO was established in 1966.
AccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #
Signal to cutoff (s/co) Copies per ml (c/ml) OVERVIEW AccuVert is a 5-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control
ANTIRETROVIRAL THERAPY IN NAMIBIA
ANTIRETROVIRAL THERAPY IN NAMIBIA SAHIVCS CONFERENCE CAPETOWN 25-28- NOVEMBER 2012 DR. F. MUGALA MUKUNGU M.MED (INT.MED) SPECIALIST PHYSICIAN KATUTURA STATE HOSPITAL WINDHOEK NAMIBIA Current status in
Drug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
Date : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark
Number 1. s 29 Jul 13 N/A Environmental Permit to construct the Passenger Clearance and associated works of the Hong Kong Zhuhai and Macao Bridge Boundary Crossing Facilities EP-353/2009/G 06 Aug 13 N/A
The International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
Point-of-care HIV testing
Point-of-care HIV testing Joanne Stekler, MD MPH Associate Professor University of Washington December 5, 2016 Disclaimer: The findings and conclusions in this presentation are those of the author(s) and
Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019
Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019 20-Jan 21-Jan 22-Jan 23-Jan 24-Jan 25-Jan 26-Jan between January 14th - January 21st Please Note: The application deadline
Sleep Market Panel. Results for June 2015
Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital
1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
The CIDRZ Experience: use of data to understand patient outcomes and guide program implementation 07 January 2010
The CIDRZ Experience: use of data to understand patient outcomes and guide program implementation 07 January 2010 Dr C Bolton Moore Deputy Medical Director CIDRZ Ministry of Health Zambia University of
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere HIV Combo WHO reference number: PQDx 0243-013-00 Alere HIV Combo with product codes 7D2842, 7D2843, 7D2843SET manufactured by Alere
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative 28 October 2008 Geneva 1 CHAI Work in Diagnostics - Context Diagnostic Test Agreements - In 2002 when CHAI was formed, the price of many
IATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
Pediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
Diagnostics: Bench to Bedside Pathway
Diagnostics: Bench to Bedside Pathway Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre London School of Hygiene & Tropical Medicine www.idx-dx.org The
HIV-1 Seroconversion Panel PRB973
A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians
ACTs in East Africa REALITY CHECK. Nathan Mulure MD Novartis Pharma
ACTs in East Africa REALITY CHECK Nathan Mulure MD Novartis Pharma 1 Agenda Introduction and background Drug resistance to antimalarials Policy change Antimalarial market Challenges 2 Malaria Burden 34,000
Article by Pasipanodya Ian Machingura 1, Adam Chindore 1. PhD Public Health, Texila American University, Zimbabwe
Diabetes Mellitus Prevalence in HIV Patients on Antiretroviral Therapy at Parirenyatwa Group of Hospitals Opportunistic Infections Clinic, Harare, Zimbabwe Article by Pasipanodya Ian Machingura 1, Adam
Quality improvement efforts in Nigerian public health facilities
Quality improvement efforts in Nigerian public health facilities A presentation of FHI Nigeria at the maiden conference of the Society for Quality Healthcare in Nigeria 7 July, 2009 Dr Christoph Hamelmann
Drug Name. Code Artesunate Injection 60 mg/ml Chloroquine Phosphate Injection 40 mg/ml
Sr.No New Drug Code Drug Name 1 26.1.275.2 Artesunate Injection 60 mg/ml 2 26.1.277.2 Chloroquine Phosphate Injection 40 mg/ml 3 26.1.277.4 Chloroquine Phosphate Tablet 250 mg, equivalent to 155 mg chloroquine
Improving Health Outcomes Through Strategic Sourcing of ARVs and Viral Load Technologies
Improving Health Outcomes Through Strategic Sourcing of ARVs and Viral Load Technologies January 2016 Geneva, Switzerland Contents I. Executive Summary... 4 II. Introduction... 5 01 The HIV/AIDS Context...
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
reductions Untangling the web of price reductions: 6th Edition eligibility pricecountries company price countries price
company price countries reductions pricecountries price eligibility reductions Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries 6th Edition 19th
Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed
Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single
Update on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
HIV SELF-TESTING AFRICA
UNITAID PSI HIV SELF-TESTING AFRICA Zambart: Interim Results of Clinical Performance Study Alwyn Mwinga Overview of Presentation Study Objectives Clinical Performance study Visual stability study Progress
Global Fund Quality Assurance Policy for Diagnostics products : collaboration with WHO DLT
Global Fund Quality Assurance Policy for Diagnostics products : collaboration with WHO DLT Pharmaceutical Management Unit Quality Assurance and Data Management Team QA for health products financed by Global
Point of Care Tests for respiratory viruses: impact on clinical outcomes of patients
Point of Care Tests for respiratory viruses: impact on clinical outcomes of patients Dr Sacha Stelzer-Braid Postdoctoral Scientist Virology Research Laboratory (VRL), UNSW and POWH @DrSachaSB Outline 1.
Progress Report on the Quantification and Planning Exercise for Antiretroviral Medicines in 2013, within the Framework of SUGEMI Implementation
Progress Report on the Quantification and Planning Exercise for Antiretroviral Medicines in 2013, within the Framework of SUGEMI Implementation Prepared by: Dirección de Desarrollo y Fortalecimiento de
Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, User s Manual
Clinton Foundation HIV/AIDS Initiative ARV Procurement Forecast Tool Version 1.4 March, 2005 User s Manual Index 1. Overview 2. Scale-Up Assumptions 3. Procurement Assumptions 4. Clinical Assumptions 5.
FGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS
AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021
Cost projections a single antiretroviral co-payment scheme for people with HIV in NSW. March 2013
Cost projections a single antiretroviral co-payment scheme for people with HIV in NSW March 2013 Background The first meeting of HIV Strategy Implementation Taskforce Committee endorsed a policy position
HIV-1 Seroconversion Panel
OVERVIEW This Data Sheet contains test results specific for HIV-1. s are undiluted aliquots from plasma units collected from a single donor. No preservatives were added. CAUTION: Potentially infectious
Early Infant Diagnosis-Malawi Experience. P.N.Kazembe
Early Infant Diagnosis-Malawi Experience P.N.Kazembe MALAWI HIV/AIDS DATA Total population 12.8 million HIV prevalence 14% (15-49 yrs) Antenatal HIV prevalence 15%. 81,000 HIV infected women deliver/yr
2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California SUNDAY, FEBRUARY 8, 2015: 10:00am - 11:00am Primary Care of the HIV Patient Presented by Jim Lee,
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites. Updated: February 2018 Cicely Richard Office of HIV/AIDS
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites Updated: February 2018 Cicely Richard Office of HIV/AIDS Updated: February 2018 Cicely Richard Office of HIV/AIDS UNIGOLD RECOMBIGEN HIV 1/2 TRAINING
Thank you for your request for information that has been processed under reference number
Corporate Development Contact us: dhft.foi@nhs.net Royal Derby Hospital Uttoxeter Road Derby DE22 3NE Tel: 01332 265500 Minicom: 01332 785566 www.derbyhospitals@nhs.uk Follow us on Twitter @DerbyHospitals
The Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
SUPPLIER/MANUFACTURER PERFORMANCE REPORT
80/30 MOO 8 PHAHOLYOTHIN RD., T.KUKHOT, A.LUMLOOKKAR, PATHUMTHANI 30, THAILAND TEL : (66-) 9958 9, 995330 FAX : (66-) SUPPLIER/MANUFACTURER PERFORMANCE REPORT 80/30 MOO 8 PHAHOLYOTHIN RD., T.KUKHOT, A.LUMLOOKKAR,